Diet Interventions in Psoriatic Arthritis

Overview

The purpose of this study is to learn whether changing diet impacts psoriatic arthritis (PsA).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2021

Detailed Description

The study asks if dietary change and nutritional support improves disease activity and if patients are better able to improve or sustain progress with additional incentives. The study will use an online program to communicate with participants through text and online surveys. This 24-week trial will enroll 90 patients in the US and Canada with New York University as a back-up site.

Interventions

  • Other: Diet 1
    • Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
  • Other: Diet 2
    • This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject’s demographics (age, sex, weight, height).

Arms, Groups and Cohorts

  • Active Comparator: Diet 1
    • Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
  • Active Comparator: Diet 2
    • Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
  • No Intervention: Diet 3
    • Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Disease Activity in Psoriatic Arthritis (DAPSA)
    • Time Frame: 12 weeks
    • Disease Activity(DAPSA): 0-4 Remission; 5-14 Low; 15-28 Moderate; > (Greater than) 28 High Disease Activity, DAPSA = TJ (Tender Joints) + SJ (Swollen Joints) + CRP (C-reactive protein) + Activity + Pain Tender Joints Count (0-68), TJ: Swollen Joints Count (0-66), SJ: CRP (mg/dl): Patient’s assessment of disease activity and pain: How active was your rheumatic disease on average during the last week? Scale of 1-10 (Not Active -Active) How would you describe the overall level of joint pain during the last week? Scale of 1-10 (None-Very Severe)

Secondary Measures

  • Change in Psoriasis Area and Severity Index (PASI)
    • Time Frame: 24 weeks
    • A measurement of the severity of psoriasis; 0 (no disease) to 72 (maximal disease)
  • Change in Disease Activity in Psoriatic Arthritis (DAPSA)
    • Time Frame: 24 weeks
    • Disease Activity(DAPSA): 0-4 Remission; 5-14 Low; 15-28 Moderate; > (Greater than) 28 High Disease Activity DAPSA = TJ + SJ + CRP + Activity + Pain Tender Joints Count (0-68), TJ: Swollen Joints Count (0-66), SJ: CRP (mg/dl): Patient’s assessment of disease activity and pain: How active was your rheumatic disease on average during the last week? Scale of 1-10 (Not Active -Active) How would you describe the overall level of joint pain during the last week? Scale of 1-10 (None-Very Severe)
  • Patient Reported Outcomes-Physical Function
    • Time Frame: Varying times: (at Baseline) 0,12, 24 Weeks
    • -Physical Function-International Physical Activity Questionnaire (IPAQ) We will examine change in physical activity over the study (as we will be advising patients not to change exercise habits). IPAQ is an instrument for assessing levels and patterns of physical activity. IPAQ has been validated in healthy adults and is publicly available, open access, and no permissions are required for use.
  • Patient Reported Outcomes-Psoriatic Arthritis Disease Impact
    • Time Frame: Varying times: (at Baseline) 0, 4, 8, 12, 16, 20, 24 Weeks
    • -Psoriatic Arthritis Disease Impact- Psoriatic Arthritis Impact of Disease (PSAID). The PsAID is a measure developed by the European League Against Rheumatism (EULAR) and is composed of domains selected by an international group of patients with psoriatic arthritis. The questionnaire uses a weighted scoring system (weights were derived by patient impression of importance) and has a range of 0-10 with 4 being considered a patient acceptable symptom state. The proposed Minimal Clinically Important Difference (MCID) is 3.
  • Patient Reported Outcomes-Skin Disease Impact
    • Time Frame: Varying times: (at Baseline) 0,12, 24 Weeks
    • -Skin Disease Impact- Psoriasis Area and Severity Index (PASI). The Psoriasis Area Severity Index (PASI) is an index used to express the severity of psoriasis. It combines the severity (erythema (redness), induration (thickness) and desquamation (peeling) and percentage of affected area. This is the primary outcome measure in trials of psoriatic arthritis.
  • Patient Reported Outcomes-Fatigue
    • Time Frame: Varying times: (at Baseline) 0, 4, 8, 12, 16, 20, 24 Weeks
    • -Fatigue- PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue (CAT) The PROMIS Fatigue scale assesses fatigue experience and impact of fatigue over 7 days. The instrument includes items on exhaustion and ability to function normally in physical, social, mental and family roles and activities. This instrument has good content validity and responsiveness in rheumatoid arthritis, a similar inflammatory arthritis. We will use the CAT (Computerized Adaptive Test) response instrument.
  • Patient Reported Outcomes-Depression
    • Time Frame: Varying times: (at Baseline) 0,12, 24 Weeks
    • -Depression- PROMIS (Patient-Reported Outcomes Measurement Information System) Depression (CAT) The PROMIS Depression assesses sadness, guilt, self-criticism, worthlessness, loneliness, loss of interest, meaning, and purpose. The PROMIS depression scale is used across diseases but has been specifically demonstrated to have good responsiveness with therapy in patients with rheumatoid arthritis. The item bank assesses symptoms over the past 7 days. (Suicidality is not assessed in this questionnaire). We will use the CAT (Computerized Adaptive Test) response instrument.
  • Metabolic Profile-Blood Pressure
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • Change in Blood Pressure Blood Pressure; BP _ systolic/diastolic; Both pressures will be assessed during the study period.
  • Metabolic Profile-Weight
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • Changes in Weight; Weight_kg; Weight and Height will be combined to report BMI in kg/m^2; Body Mass Index (BMI) _ wt/h²; The standard weight status categories associated with BMI ranges for adults are listed as; BMI Weight Status: Below 18.5 Underweight 18.5 – 24.9 Normal or Healthy Weight 25.0 – 29.9 Overweight 30.0 and Above Obese Accessed on 11/19/19, https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html#Interpreted
  • Metabolic Profile-Height
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • Height_M; Height and Weight will be combined to report BMI in kg/m^2
  • Metabolic Profile-Waist Measurement
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • Waist measurement_cm
  • Metabolic Profile- Blood Glucose Studies
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • Blood Glucose Studies-HbA1C; HbA1c___________ % Normal: HbA1c below 5.7% Prediabetes: HbA1c between 5.7% and 6.4 Diabetes: HbA1c of 6.5% or higher; Accessed on 11/19/19, https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/
  • Metabolic Profile- C-reactive protein
    • Time Frame: Varying times: (at Baseline) 0, 12, 24 Weeks
    • C-reactive protein: General index used for inflammation
  • Therapy changes
    • Time Frame: Chart review at 12 and 24 Weeks
    • Any changes in medications therapies will be recorded (in particular psoriatic arthritis medications, NSAIDs, cholesterol medications, high blood pressure medications, and Type 2 diabetes medications).
  • Preliminary Safety: Adverse event (AE)/ Serious Adverse Event (SAE)
    • Time Frame: 12 Weeks, 24 Weeks
    • AEs and SAEs are reported separately. Participants can report an adverse event at any time but will be asked about it at 12 weeks and analyzed at 24 weeks.

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18-80 – Required Rheumatologist-confirmed diagnosis of PsA fulfilling Classification of Psoriatic Arthritis Criteria (CASPAR) – Willing to alter diet and participate for 24 weeks – Able to attend follow-up visits – Body mass index (BMI) > 25 and <40 – No history of eating disorders such as anorexia or bulimia – Disease Activity in Psoriatic Arthritis Assessment (DAPSA) > 10 – Stable treatment for PsA for ≥3 months prior to enrollment (patients may be on any disease modifying anti-rheumatic drugs (DMARDs) or they can be free of systemic medications – Owns and uses an iPhone or Android smart phone, or is willing to use a device provided by the study team Exclusion Criteria:

  • Inability to provide informed consent – Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks – Use of systemic corticosteroids – All persons who would be placed at an increased risk including any medical condition that will impair the ability of the person to participate in a nutritional intervention study (e.g. insulin dependent diabetes, use of coumadin, advanced malignancy, inflammatory bowel disease, dementia) – History of food allergy to any of the components of olive oil or nuts – Inability to read and write in English – Unwillingness to change dietary habits – Known pregnancy (pregnancy testing will be performed for women of childbearing age; weight changes will not accurately reflect the changes we would anticipate in pregnant patients and weight loss may be detrimental to maternal and/or fetal outcomes). – Participation in another physical activity study and/or diet trial

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Collaborator
    • Women’s College Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alexis Ogdie-Beatty, MD, MSCE, Principal Investigator, University of Pennsylvania
    • Lihi Eder, MD, PhD, Principal Investigator, Women’s College Hospital, University of Toronto
  • Overall Contact(s)
    • Michele Almonte, BSN RN, 215-349-5261, michele.almonte@pennmedicine.upenn.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.